| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-255 | |
| Phytochemical name or plant extracts | Safflower yellow (SY) | |
| PMID | 27776431 | |
| Literature evidence | We suggest that SY should be considered as a potential novel therapeutic agent for the treatment of breast cancer. | |
| IUPAC name | (2Z,6S)-5,6-dihydroxy-4-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-[[(3S)-2,3,4-trihydroxy-5-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-6-oxo-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohexa-1,4-dien-1-yl]methylidene]cyclohex-4-ene-1,3-dione | |
| Phytochemicals’ class or type of plant extracts | Hydroxycinnamic acid | |
| Source of phytochemicals or plant Extracts | Carthamus tinctorius | |
| Geographical availability | Iran, Turkey | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | MMP9, p-Src | |
| Gene or Protein evidence | Consistent with these phenotypes, formation of invadopodia and the expression of MMP-9 and p-Src proteins were decreased after EGF stimulation in MBA-MD-231 cells treat with SY, as well as in lung metastatic foci. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | We suggest that SY should be considered as a potential novel therapeutic agent for the treatment of breast cancer. | |
| Cell line/ mice model | MBA-MD-231 | |
| Additional information | SY could dose-dependently inhibit EGF-mediated time- and dose-dependent cell response profiles by inhibiting cytoskeletal rearrangement. We also found that SY significantly inhibited the migration of breast cancer cells in vitro and pulmonary metastasis of breast cancer cells in vivo. | |
| PubChem ID | 135565560 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:324467-2 | |
| Safety | NA |